Scientists at Oxford University, United Kingdom, have commenced a clinical trial for a novel HIV vaccine. The trial known as HIV-CORE 0052 began on Monday. The goal of the trial, according to Oxford, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

For this clinical trial, 13 healthy adults aged between 18–65 who were considered not to be at high risk of infection received one dose of the vaccine which will be followed by a further booster dose at four weeks.